CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodi... ( Believed by experts to be import...)

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

Date:5/14/2008

Believed by experts to be important for cervical cancer prevention

GRAZ, Austria, May 14 /PRNewswire-FirstCall/ -- New data from an extended follow-up study show that GlaxoSmithKline (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX(R) generates sustained high levels of neutralizing antibodies against the two most common cervical cancer-causing human papillomavirus types for up to 6.4 years. This is the longest duration of sustained neutralizing antibody levels observed against both virus types 16 and 18 with a cervical cancer vaccine to date.

Experts believe that neutralizing antibodies -- so-called because they have the ability to neutralize cancer-causing virus types and prevent them from infecting cells in the cervix -- are essential for cervical cancer protection. The World Health Organization has stated that neutralizing antibodies are "considered to be the major basis" of vaccine-induced protection from infection.

In addition, the study found that the level of total antibodies induced by the candidate vaccine was sustained and 11 times higher than the total antibody levels induced after natural infection for up to 6.4 years. This new data confirms previous findings from the vaccine's studies showing that, when total antibody levels are high, neutralizing antibody levels are also elevated.

"We designed our cervical cancer vaccine with our proprietary Adjuvant System, AS04, to deliver high and sustained levels of neutralizing antibodies to prevent cervical cancer over the long-term," said Philippe Monteyne, Senior Vice President, GSK Biologicals. "With nearly six and a half years of data, the vaccine has already been shown to provide the longest duration of protection of any cervical cancer vaccine t
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
3. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
4. Evotecs EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
9. Raptor Pharmaceuticals Provides Update of Product Programs
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial

Post Your Comments:

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodi...( Believed by experts to be import...),Health